The Return of American Manufacturing Demands a Chief Health & Benefits Officer (CHBO) to Fix Benefits Procurement

By MATT McCORD American manufacturing is making a comeback. Driven by tariffs, supply chain instability, and shifting economic priorities, companies are reshoring production—reinvesting in U.S. labor and operations. But there’s one major obstacle still standing in the way: the crushing cost of American healthcare. For decades, U.S. employers have overpaid for healthcare without improving outcomes….

Read More

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria

That is the tile of my recent paper in the Journal of Medical Economics with co-authors Kyi-Sin Than, Sanjana Muthukrishnan, Jincy Paulose, Ver Bilano and Nicholas Kuypers. The abstract is below: ObjectiveParoxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a…

Read More